Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.

Dec 19, 2024 · Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy – Treatment with the highly selective NaV1.8 pain …

At Vertex, the world’s most talented and passionate people come together to advance science and transform lives, and in return, we invest in them so they can grow and advance their own …

Dec 20, 2024 · Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - ALYFTREK ™ is approved for patients …

Jan 13, 2025 · Vertex plans to share Part B full-dose data from the VX-264 Phase 1/2 study in 2025. Vertex is also pursuing alternative approaches to immunosuppression that could be …

Read the following terms and conditions of use for the Vertex Pharmaceuticals Website.

Dec 20, 2024 · BOSTON--(BUSINESS WIRE)--Dec. 20, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) …

Vertex Pharmaceuticals provides a range of comprehensive benefit options which enable you to setup your ideal mix of health and well-being selections.

Vertex is focused on discovering, developing and producing innovative medicines so people with serious diseases can lead better lives. Our scientists don’t see the impossible as an obstacle; …

The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.